WO2007145993B1 - Modified compositions and methods for enhancing brain function - Google Patents

Modified compositions and methods for enhancing brain function

Info

Publication number
WO2007145993B1
WO2007145993B1 PCT/US2007/013316 US2007013316W WO2007145993B1 WO 2007145993 B1 WO2007145993 B1 WO 2007145993B1 US 2007013316 W US2007013316 W US 2007013316W WO 2007145993 B1 WO2007145993 B1 WO 2007145993B1
Authority
WO
WIPO (PCT)
Prior art keywords
present
amount
supplement
nutritional supplement
rhodiola
Prior art date
Application number
PCT/US2007/013316
Other languages
French (fr)
Other versions
WO2007145993A2 (en
WO2007145993A3 (en
Inventor
Josh Reynolds
Original Assignee
Brite Age
Josh Reynolds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brite Age, Josh Reynolds filed Critical Brite Age
Publication of WO2007145993A2 publication Critical patent/WO2007145993A2/en
Publication of WO2007145993A3 publication Critical patent/WO2007145993A3/en
Publication of WO2007145993B1 publication Critical patent/WO2007145993B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Clinical studies have proven that contemplated compositions achieve specific improvements in cognition using a modified nootropic formulation having six active ingredients at or near threshold active dosages. Most preferably, the active ingredients are huperzine A, vinpocetine, acetyl-L-carnitine, alpha lipoic acid, rhodiola, and biotin at typically less than 2300 mg per daily dosage.

Claims

AMENDED CLAIMS received by the International Bureau on 01 August 2008 (01.08.2008)
What is claimed is:
1 - A nutritional supplement Tor enhancing cognitive function, comprising a group of active ingredients consisting of huperκiπe A, vinpocetine, acctyl~L-camitine, alpha lipoic acid, rhodiola, and biotin.
2. The nutritional supplement of claim 1 wherein the hupcrzine A5 the vinpocetine, and the acety]-L-carnitine arc present in u ratio of x : y : z, wherein x is between 0.8 and 1.2, y is between 80 and 120. and z is between 8,000 and 12,000.
1. The nutritional supplement of claim 1 wherein a ratio between the acctyl-L-carnitine and the alpha lipoic acid, the rhodiola, and the biotin is between 2: 1 and 20:1 , between 2: 1 and 20: 1 , and between 20.000: 1 and 200: 1 , respectively.
4. The nutritional supplement of claim 1 wherein in a daily dose huperκine A is present in an amount between 100-200 meg, vinpocetine is present ill an amount between 10- 30 mg, and acetyl- L-carnitinc is an amount between 1 ,500-2,000 mg.
5. The nutritional supplement of claim 1 wherein in a daily dose alpha lipoic acid is present in an amount between 250-500 mg, rhodiola is present in an amount between 200-400 mg, and biotin is present in an amount between 250-750 meg.
6. The nutritional supplement of claim 4 wherein in a daily dose alpha lipoic acid is present in an amount between 250-500 mg, rhodiola is present in an amount between 200-400 mg, and biotin is present in an amount between 250-750 meg.
7. The nutritional supplement of claim I further comprising an inactive ingredient is selected from the group consisting of a carrier, a binder, an excipient, and a dye.
8. The nutritional supplement of claim 1 wherein the huperisine A, vinpocetine, and acetyl -T ,-carnitine together account for at least 50 wt% of a dosage unit of the supplement, excluding inactive ingredients.
9. The nutritional supplement of claim 1 wherein the supplement is formulated for oral administration such that the group of active ingredients accounts for at least 85 wt% of a dosage unit of the supplement.
25
10. The nutritional supplement of claim 1 wherein the supplement is formulated for oral administration such that the group of active ingredients accounts for at least 90 wt% of a dosage unit of the supplcment.
11. The nutritional supplement of claim 1 wherein the daily dosage of the supplement is equal or less than 2,300 mg.
12. The nutritional supplement of claim 1 further comprising an. information slating that the nutritional supplement enhances at least one of working memory, general intelligence, attention, and mood.
13. Λ method of assisting enhancement of cognitive function in a person using a nutritional supplement, comprising: providing a composition lhat includes a group of active ingredients consisting of huperzinc Λ, vinpocetine, acelyl-L-carnitine, alpha iipoic acid, rhodiola, and biotin; formulating the supplement for oral administration such that the active ingredients together account for at least 90 wt% of a dosage unit of the supplement. excluding inactive ingredients; and providing an information that the supplement in a clinical trial was effective to improve cognitive function.
14. The method of claim 13 wherein the huperzinc A, the vinpoceLine, and the acetyl-L- camitine are present in a ratio of x : y : z, wherein x is between 0.8 and 1.2, y is between 80 and 120, and z is between 8,000 and 12,000.
15. The method of claim 13 wherein a ratio between the acetyl -L-carni tine and the alpha Iipoic acid, the rhodiola, and the biotin is between 2: 1 and 20: 1 , between 2:1 and 20: 1 , and between 20,000:1 and 200:1 , respectively.
16. The method of claim 13 wherein in a daily dose huperzinc A is present in an amount between 100-200 meg, vinpocetine is present in an amount between 10-30 mg, and acelyl-L-eamiline is an amount between 1 ,500-2,000 mg.
17. The method of claim 13 wherein in a daily dυse alpha lipoic acid is present in an amount between 250-500 mg. rhodiola is present in an amount between 200-400 mg, and biotin is present in an amount between 250-750 meg.
18. ihe method of claim 16 wherein in a daily dose alpha lipoic acid is present in an amounl between 250-500 mg, rhodiola is present in an amount between 200-400 mg, and biotin is present in an amount between 250-750 meg.
19. The method of claim 13 wherein the cognitive function is at least one of working memory, general intelligence, attention, and mood.
20. The method of claim 13 further comprising a step o P providing an interactive tool that allows at least one of validation of efficacy of the supplement arid proper personal dosing of the supplement.
27
PCT/US2007/013316 2006-06-05 2007-06-05 Modified compositions and methods for enhancing brain function WO2007145993A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80394306P 2006-06-05 2006-06-05
US60/803,943 2006-06-05
US82020106P 2006-07-24 2006-07-24
US60/820,201 2006-07-24

Publications (3)

Publication Number Publication Date
WO2007145993A2 WO2007145993A2 (en) 2007-12-21
WO2007145993A3 WO2007145993A3 (en) 2008-08-14
WO2007145993B1 true WO2007145993B1 (en) 2008-09-25

Family

ID=38832348

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/013316 WO2007145993A2 (en) 2006-06-05 2007-06-05 Modified compositions and methods for enhancing brain function
PCT/US2007/013376 WO2008002382A1 (en) 2006-06-05 2007-06-06 Compositions and methods for enhancing brain function

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013376 WO2008002382A1 (en) 2006-06-05 2007-06-06 Compositions and methods for enhancing brain function

Country Status (1)

Country Link
WO (2) WO2007145993A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103539A2 (en) 2009-03-09 2010-09-16 Dinesh Shantilal Patel Sustained release oral formulation of vinpocetine
WO2011029176A1 (en) * 2009-09-14 2011-03-17 Michael Scott Buckley Concentration and mental performance amplifying formulation
AU2014235034A1 (en) * 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US7115285B2 (en) * 2003-03-14 2006-10-03 Eurark, Llc Composition and method for appetite and craving suppression and mood enhancement
US20050053904A1 (en) * 2003-08-13 2005-03-10 Jennifer Shephard System and method for on-site cognitive efficacy assessment

Also Published As

Publication number Publication date
WO2007145993A2 (en) 2007-12-21
WO2008002382A1 (en) 2008-01-03
WO2007145993A3 (en) 2008-08-14
WO2008002382B1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
US7335384B2 (en) Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
US20060233892A1 (en) Topiramate compositions for treatment of headache
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
JP2018016648A (en) Medicinal composition for external use containing luliconazole
HK1085390A1 (en) Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases
JP2001527541A (en) Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
CA2416492A1 (en) Treatment of glycogen storage disease type ii
TW200716144A (en) Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
RU2008119454A (en) MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS
JP6574809B2 (en) Compositions and methods for the treatment of chronic fatigue
JP2013526611A5 (en)
ECSP088348A (en) IRON SUPPLEMENT COMPOSITIONS WITH IMPROVED TOLERANCE
WO2007145993B1 (en) Modified compositions and methods for enhancing brain function
JP7291079B2 (en) How to reduce symptoms of PMS
US8197871B2 (en) Composition for headache treatment
MXPA05009781A (en) Antitumor effect potentiator and antitumor agent.
US6979468B1 (en) Oral composition and method for the treatment of inflammatory cutaneous disorders
US20030194453A1 (en) Dietary supplement
KR20100086560A (en) Nanocomposite comprising vitamin c for preventing hair loss and enhancing hair restoration, composition comprising the nanocomposite
WO2004006908A1 (en) Remedies for pigmentation
US9642885B2 (en) Blood pressure reduction with dietary supplements
AU754329B2 (en) Fungicide composition comprising a benzoylphenylurea
US8529950B2 (en) Magnesium system and use thereof in the cosmetics industry
TW200626133A (en) Oral medication for twice-daily administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809354

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07809354

Country of ref document: EP

Kind code of ref document: A2